Citations

Clear

9383 citation(s) found for "Thomas, PS".

Mechanisms and Utility of Discrete Great Arterial Potentials in the Ablation of Outflow Tract Ventricular Arrhythmias
Bunch, T. Jared , Asirvatham, Samuel J. , Edwards, William D. , Friedman, Paul A. , Munger, Thomas M. , Hammill, Stephen C., Cha, Yong‐Mei , Brady, Peter A. , Rea, Robert F., Packer, Douglas L. , Shen, Win-Kuang, Srivathsan, Komandoor , Jahangir, Arshad , Bradley, David J. , Asirvatham, Samuel J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | June 5, 2008 | Volume: 1 | Issue: 1 | Pages: 30-38

10.1161/circep.107.750315 | PMID 19808391 Get It

Background— Outflow tract ventricular tachycardia originating above the semilunar valves has been reported in a small number of studies. Discrete potentials in the great arteries (above the semilunar valves) have been rarely described in patients undergoing electrophysiology evaluation and radiofrequency ablation for ventricular arrhythmias. The mechanisms of these discrete potentials in the great arteries and the utility of such potentials in guiding radiofrequency ablation are unknown. Methods and Results— Twelve patients with outflow tract ventricular arrhythmia originating above the semilunar valves with discrete arterial potentials were studied. The clinical characteristics, properties of the arterial potentials, electrophysiological evaluation and ablation, and short- and long-term outcomes were reviewed. Of the twelve patients, 8 (67%) were women. The patients’ average age was 41�14 years. The average ejection fraction was 0.52�0.16 (range: 0.16 to 0.75). Contact mapping in the great artery demonstrated discrete near-field electrograms that were separate from far-field ventricular electrograms in all patients (8 above the pulmonary valve and in 4 the aortic valve). One or more of the following electrophysiological characteristics, supportive of an arrhythmogenic substrate, were observed in 10 of 12 patients: (1) A fixed or reproducibly variable pattern of discrete potential–ventricular arrhythmia relationship was present at baseline or during pacing; (2) the discrete potential–ventricular electrogram relationship during sinus rhythm was the reverse of that during the ventricular arrhythmia; (3) during sustained ventricular tachycardia, spontaneous variation of the ventricular (V-V) cycle length was preceded by a similar variation of arterial spike potential–spike potential cycle length; and (4) ablation guided by the discrete arterial potential successfully eliminated the clinical arrhythmia. Ablation was successful in these patients. In the remaining 2 patients, the potentials were believed to be bystanders. Over 10�4 months (range: 5 to 32 months) of follow-up, there have been no recurrences of the premature ventricular complex or ventricular arrhythmia. Conclusions— Discrete potentials are present in the great arteries of a select group of patients with outflow tract ventricular tachycardia originating above the semilunar valves. When an arrhythmogenic relationship can be demonstrated, discrete potentials are useful in guiding ablation within the great vessels, despite significant anatomic complexity.
Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index
Sierra‐Johnson, Justo, Romero‐Corral, Abel, Thomas, Randal J. , Squires, Ray W. , Allison, Thomas G. , Somers, Virend K. , López-Jiménez, Francisco , Thomas, Randal

Mayo Clinic

European Journal of Cardiovascular Prevention & Rehabilitation | June 4, 2008 | Volume: 15 | Issue: 3 | Pages: 336-340

10.1097/hjr.0b013e3282f48348 | PMID 18525390 Get It

MicroRNA Signatures as Diagnostic and Therapeutic Targets
Waldman, Scott A. , Terzic, André , Waldman, Scott A

Mayo Clinic

Clinical Chemistry | May 28, 2008 | Volume: 54 | Issue: 6 | Pages: 943-944

10.1373/clinchem.2008.105353 | PMID 18509012 Get It

Biochemical Correction of Short-Chain Acyl-Coenzyme A Dehydrogenase Deficiency After Portal Vein Injection of rAAV8-SCAD
Beattie, Stuart G. , Conlon, Thomas J. , Germain, Sean, Walter, Glenn A. , Campbell‐Thompson, Martha , Matern, Dietrich , Vockley, Jerry , Flotte, Terence R. , Goetzman, Eric S.

Mayo Clinic

Human Gene Therapy | May 26, 2008 | Volume: 19 | Issue: 6 | Pages: 579-588

10.1089/hum.2007.168 | PMID 18500942 Get It

Robot-Assisted Extended Pelvic Lymphadenectomy
Thomas, Raju , Davis, Rodney , Andrews, Paul E. , Ferrigni, Robert G., Cheng, Joan, Castle, Eric, Woods, Michael E.

Mayo Clinic

Journal of Endourology | May 22, 2008 | Volume: 22 | Issue: 6 | Pages: 1297-1302

10.1089/end.2008.0075 | PMID 18498233 Get It

Estrogen Receptor β Isoform-Specific Induction of Transforming Growth Factor β-Inducible Early Gene-1 in Human Osteoblast Cells: An Essential Role for the Activation Function 1 Domain
Hawse, John R. , Subramaniam, Malayannan , Hemmingsen, Amanda Heather, Khosla, Sundeep , Oursler, Merry Jo, Spelsberg, Thomas C., Monroe, David G. , Ingle, James N. , Khosla, Sundeep

Mayo Clinic

Molecular Endocrinology | May 16, 2008 | Volume: 22 | Issue: 7 | Pages: 1579-1595

10.1210/me.2007-0253 | PMID 18483178 Get It

Abstract The estrogen receptors (ER) α and β are important ligand-mediated transcription factors known to play significant biological roles in numerous tissues including bone. Despite the high homology shared by these receptors, recent studies have suggested that their function is largely unique. Although these receptors have been studied in detail for more than a decade, little data exist concerning the mechanisms by which these two proteins regulate distinct sets of genes. Using the TGFβ-inducible early gene-1 (TIEG) as a model, we demonstrate that TIEG is rapidly induced in response to estrogen in osteoblasts by ERβ, but not ERα. We have identified the regulatory elements utilized by ERβ and have demonstrated that ERβ recruits steroid receptor coactivator (SRC)1 and SRC2 to this regulatory region. Additionally, deletion of the ERβ-activation function 1 (AF1) domain drastically decreases the estrogen induction of TIEG. Through the use of chimeric receptors, we have demonstrated that the AF1 domain of ERβ is responsible for recruiting SRC1 and SRC2 and inducing the expression of TIEG in osteoblasts. Finally, SRC1, but not SRC2, is essential for TIEG induction by ERβ. Overall, these data demonstrate that the estrogen induction of TIEG is ERβ specific and that the AF1 domain of ERβ confers this specificity. Finally, a novel and important role for ERβ’s AF1 is implicated in the recruitment of specific coactivators, suggesting that the AF1 may play a significant role in conferring the differences in regulation of gene expression by these two receptors.
The Effects of Growth Hormone and/or Testosterone on Whole Body Protein Kinetics and Skeletal Muscle Gene Expression in Healthy Elderly Men: A Randomized Controlled Trial
Giannoulis, Manthos G., Shojaee‐Moradie, Fariba , Sönksen, Peter H. , Umpleby, A. Margot , Jackson, Nicola C. , Nair, K. Sreekumaran , Martin, Finbarr C.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | May 13, 2008 | Volume: 93 | Issue: 8 | Pages: 3066-3074

10.1210/jc.2007-2695 | PMID 18477661 Get It

Catheter Ablation for Atrial Fibrillation in Patients With Obesity
Cha, Yong‐Mei , Friedman, Paul A. , Asirvatham, Samuel J. , Shen, Win-Kuang, Munger, Thomas M. , Rea, Robert F., Brady, Peter A. , Monahan, Kristi H. , Hodge, David O. , Meverden, Ryan A., Hammill, Stephen C., Packer, Douglas L. , Jahangir, Arshad , Gersh, Bernard J. , Asirvatham, Samuel J

Mayo Clinic

Circulation | May 13, 2008 | Volume: 117 | Issue: 20 | Pages: 2583-2590

10.1161/circulationaha.107.716712 | PMID 18474813 Get It

Background— Obesity is a risk factor for atrial fibrillation and other cardiovascular conditions. Our objective was to determine whether catheter-based ablation effectively treated atrial fibrillation in obese patients. Methods and Results— Five hundred twenty-three consecutive patients with symptomatic, medication-refractory atrial fibrillation underwent catheter ablation. Patients were grouped by body mass index (lean, <25 kg/m 2 ; overweight, 25 to 29.9 kg/m 2 ; obese, ≥30 kg/m 2 ). Outcome and quality of life were measured with a general health survey (Medical Outcomes Study 36-item Short-Form General Health Survey [SF-36]); patients were assessed before ablation and at 3 and 12 months after the procedure. Two hundred twenty-eight study patients (44%) were overweight, and 201 (38%) were obese. Twelve months after curative ablation, 72% of patients were free of atrial fibrillation without the use of antiarrhythmic agents; 84% were arrhythmia free when those receiving medication were included. Atrial fibrillation was eliminated in 75%, 72%, and 70% of the lean, overweight, and obese patients, respectively, at 12 months ( P =0.41, trend test). SF-36 scores were lower for patients with higher body mass index ( P <0.05) at baseline. SF-36 scores improved in every functional domain for all body mass index groups after ablation. The mean SF-36 total physical score increased from 59±20 at baseline to 77±19 in 12 months ( P <0.001). The total mental health score improved from 66±18 to 79±16 in 12 months ( P <0.001). Conclusions— Catheter ablation of atrial fibrillation was effective in obese patients. Coexistence of atrial fibrillation and obesity indicated lower SF-36 scores, but the improvement in quality of life was consistent across all body mass index categories.
Mild traumatic brain injury: Continued investigation and controversy
Bergquist, Thomas F. , Nehl, Carissa

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | May 12, 2008 | Volume: 30 | Issue: 7 | Pages: 850-852

10.1080/13803390801940740 Get It

Karyotype Evolution on Fluorescent In Situ Hybridization Analysis Is Associated With Short Survival in Patients With Chronic Lymphocytic Leukemia and Is Related to CD49d Expression
Hanson, Curtis A. , Dewald, Gordon W., LaPlant, Betsy, Abrahamzon, Jennifer L., Jelinek, Diane F., Shanafelt, Tait D. , Witzig, Thomas E. , Kay, Neil E.

Mayo Clinic

Journal of Clinical Oncology | May 8, 2008 | Volume: 26 | Issue: 14 | Pages: e5-e6

10.1200/jco.2008.16.7874 | PMID 18467710 Get It